Skip to main content

Table 1 Baseline characteristics

From: Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry

  Etanercept cohort (N = 2725) Biologic-naïve cohort (N = 1517) p
Gender, female 1829 (67.1) 1023 (67.4) 0.8
Age at onset (years) 7.9 ± 4.7 7.7 ± 4.6 0.18
Age at baseline (years) 12.1 ± 4.4 9.8 ± 4.8 < 0.0001*
Disease duration (years) 4.1 ± 3.7 2.1 ± 2.8 < 0.0001*
JIA category
 Systemic JIA 146 (5.3) 58 (3.8) 0.025*
 RF-negative polyarthritis 904 (33.1) 415 (27.3) < 0.0001*
 RF-positive polyarthritis 223 (8.1) 52 (3.4) < 0.0001*
 Persistent oligoarthritis 120 (4.4) 390 (25.7) < 0.0001*
 Extended oligoarthritis 570 (20.9) 204 (13.4) < 0.0001*
 ERA 486 (17.8) 213 (14.0) 0.001*
 PsA 191 (7.0) 138 (9.0) 0.017*
 Unclassified JIA 85 (3.1) 47 (3.0) 1.0
ANA 1290 (47.3) 725 (47.8) 0.8
HLA-B27 643 (23.6) 265 (17.5) < 0.0001*
Pretreatment at baseline
 NSAIDs 2478 (90.9) 1329 (87.6) 0.0007*
 Systemic steroids 1434 (52.6) 357 (23.5) < 0.0001*
 MTX 2358 (86.5) 0 (0) < 0.0001*
 Biologics 114 (4.2) 0 (0) < 0.0001*
 Other DMARDs 1232 (45.2) 149 (9.8) < 0.0001*
  SFZ 415 (15.2) 67 (4.4) < 0.0001*
  HCQ 228 (8.4) 53 (3.5) < 0.0001*
  AZA 237 (8.7) 14 (0.9) < 0.0001*
  LEF 85 (3.1) 6 (0.4) < 0.0001*
  CSA 140 (5.1) 8 (0.5) < 0.0001*
  Chlorambucil 19 (0.7) 0 (0) 0.0004*
  Cyclophosphamide 10 (0.4) 0 (0) 0.0175*
  Gold salts 36 (1.3) 0 (0) < 0.0001*
  Immunoglobulins 48 (1.8) 1 (0.1) < 0.0001*
  MMF 14 (0.5) 0 (0) 0.0034*
Concomitant treatment at baseline
 NSAIDs 2158 (79.2) 360 (23.7) 0.0001*
 Systemic steroids 974 (35.7) 1394 (91.9) 0.0001*
 MTX 1867 (68.5) 1517 (100.0) < 0.0001*
 Other DMARDs
  SFZ 145 (5.3) 36 (2.4) 0.0001*
  HCQ 37 (1.4) 14 (0.9) 0.24
  AZA 80 (2.9) 4 (0.3) 0.0001*
  LEF 59 (2.2) 1 (0.1) 0.0001*
  CSA 57 (2.1) 2 (0.1) 0.0001*
Disease activity parameters at baseline
 Active joints 6.7 ± 8.1 5.8 ± 7.6 0.0004*
 Swollen joints 5.3 ± 7.4 4.8 ± 6.8 0.03*
 Tender joints 6.5 ± 8.4 5.8 ± 7.8 0.007*
 PhysVAS 52.2 ± 32.3 47.2 ± 25.9 0.0001*
 PatVAS 43.7 ± 27.4 39.0 ± 26.0 0.0001*
 Joints with LOM 7.4 ± 8.9 5.7 ± 7.6 0.0001*
 CHAQ-DI 0.7 ± 0.6 0.6 ± 0.6 0.0001*
 ESR (mm/h) 23.5 ± 23.4 24.2 ± 23.0 0.35
 CRP (mg/L) 16.8 ± 32.7 13.9 ± 27.9 0.004*
 JADAS10 15.3 ± 7.5 13.9 ± 7.1 0.0001*
  1. Data are shown as n (%), mean ± SD, or n
  2. JIA juvenile idiopathic arthritis, RF rheumatoid factor, ERA enthesitis-related arthritis, PsA psoriatic arthritis, ANAs antinuclear antibodies, HLA human leucocyte antigen, NSAID nonsteroidal anti-inflammatory drug, MTX methotrexate, DMARD disease-modifying anti-rheumatic drug, SFZ sulfasalazine, HCQ hydroxychloroquine, AZA azathioprine, LEF leflunomide, CSA cyclosporine, PhysVAS physician global assessment of overall well-being, PatVAS parent/patient global assessment of overall well-being, LOM limitation of motion, CHAQ-DI Childhood Health Assessment Questionnaire disability index, ESR erythrocyte sedimentation rate, CRP C-reactive protein, JADAS10 10-joint Juvenile Arthritis Disease Activity Score
  3. By t test or Fisher’s exact test, as appropriate
  4. *p < 0.05